# US 2023/0055103 A1 · Methods for the diagnosis of lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055103 A1
- Document ID: US20230055103A1
- Status: Published application
- Kind: A1
- Application number: 17/593,403
- Filed: 2020-03-19
- Published: 2023-02-23
- Earliest claimed: 2019-03-19
- Assignees: Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron; Institució Catalana De Recerca↑Estudis AvançAts; Peptomyc, S.L.
- Applicants: Fundació Privada Institut D'Investigació OncolòGica De Vall Hebron; Institució Catalana De Recerca | Estudis AvançAts; Peptomyc, S.L.
- Inventors: Laura SOUCEK; Marie-Eve BEAULIEU
- Web page: https://patentgrep.com/patent/US20230055103A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 9/0043: {Nose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to the diagnostic uses of a conjugate comprising Omomyc or a functionally equivalent variant thereof and a detectable label for detecting lung cancer by pulmonary administration of the conjugate. The invention also relates to a method for detecting or imaging lung cancer using said conjugates, kits comprising said conjugates and conjugates comprising a contrast agent or an imaging agent.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A method for detecting or imaging lung cancer cells in a subject comprising:
i) administering by a pulmonary route a conjugate comprising a polypeptide comprising the sequence SEQ ID NO: 1 or a functionally equivalent variant thereof, and a detectable label;
ii) waiting a sufficient time to allow for the conjugate to enter into the proliferating lung cells; and
iii) detecting the proliferating lung cells by applying an imaging technique to the subject to detect the site of accumulation of the conjugate in the subject, thereby detecting or imaging the site of proliferation.

### Claim 25 (depends on 24)

A diagnostic method for the detection of a lung tumour in a subject comprising:
i) detecting or imaging lung cancer cells in a subject by the method according to claim 24, and further
ii) identifying a lung tumour if a specific label is detected.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the functionally equivalent variant of SEQ ID NO: 1 is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO;
6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the detectable label is selected from the group consisting of 18F, 32P 33P, 45Ti, 47Sc, 52Fe, 59Fe, 62Cu, 64Cu, 67Ga, 68Ga, 75Sc, 77As, 86Y, 89Sr, 89Zr, 94Tc, 94Tc, 99mTc, 99Mo, 105Pd, 15Rh, 111Ag, 123I, 124I, 142Pr, 143Pr, 149Pm, 153Sm, 154-1581Gd, 161Tb, 166Dy, 166Ho, 169Er, 175Lu, 186Re, 189Re, 194Ir. 198Au, 199Au, 211Pb, 212Bi, 212Pb, 223Ra and 225Ac and 89Zr.

### Claim 28 (depends on 25)

The method according to claim 25, wherein the imaging technique is mPET/mCT imaging.

### Claim 29 (depends on 25)

The method according to claim 25, wherein the lung tumour is a primary tumour selected from small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), or is a cancer metastasis.

### Claim 30 (depends on 25)

The method according to claim 25, wherein the lung tumour is adenocarcinoma.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the adenocarcinoma is a KRAS-mutant adenocarcinoma.

### Claim 32 (depends on 25)

The method according to claim 25, wherein the detection of the site of accumulation of the conjugate is carried out between 30 minutes and 96 hours after the administration of the conjugate to a subject in need thereof.

### Claim 33 (depends on 25)

The method according to claim 25, wherein the administration by pulmonary route is carried out by nasal instillation, nasal inhalation or oral inhalation.

### Claim 34 (depends on 25)

The method according to claim 25, wherein the dose of the conjugate ranges from 0.04 to 0.8 mg/Kg, or from 1.48 to 30 mg/m2.

### Claim 35 (depends on 25)

The method according to claim 25, further comprising administering the conjugate at least one more time for monitoring the progression of the lung tumour or the effect of a therapy administered to the subject.

### Claim 36 (depends on 25)

The method according to claim 25, wherein said method is carried out by using a kit comprising:
(i) a conjugate comprising a polypeptide comprising the sequence SEQ ID NO: 1 or a functionally equivalent variant thereof, and a detectable label;
(ii) a device for the pulmonary administration of the conjugate of item (i); and
(iii) means for packaging items (i) and (ii).

### Claim 37

Kit for the diagnosis of lung cancer comprising:
(i) a conjugate comprising a polypeptide comprising the sequence SEQ ID NO: 1 or a functionally equivalent variant thereof, and a detectable label;
(ii) a device for the pulmonary administration of the conjugate of item (i); and
(iii) means for packaging items (i) and (ii).

### Claim 38

A conjugate comprising:
i) a polypeptide comprising the sequence SEQ ID NO: 1 or a functionally equivalent variant thereof, and
ii) a detectable label selected from the group consisting of a contrast agent or an imaging agent.

### Claim 39 (depends on 25)

A method for treating a subject having lung cancer wherein said method comprises:
(i) selecting a subject as suffering from lung cancer by a method according to claim 25, and
(ii) administering to the subject identified with lung cancer a treatment selected from surgical removal of the lung tumor and/or administration of a chemotherapy and/or a radiotherapy.

### Claim 40 (depends on 24)

A method for monitoring the progression of lung cancer in a subject, the method comprising:
(i) detecting or imaging lung cancer cells in the subject by a method according to claim 24, and
(ii) comparing the site of accumulation obtained in (i) with the site of accumulation obtained in a previous measure,
wherein a significant decrease or lack of change in the site of accumulation in comparison with the previous measure is indicative that the lung cancer is not progressing, or
wherein a significant increase in the site of accumulation in comparison with the previous measure is indicative that the lung cancer is progressing.

### Claim 41 (depends on 24)

A method for monitoring the response to a therapy in a subject suffering from lung cancer, the method comprising:
(i) detecting or imaging lung cancer cells in the subject by a method according to claim 24, and
(ii) comparing the site of accumulation obtained in (i) with the site of accumulation obtained in a previous measure prior to administration of the therapy,
wherein a significant decrease or lack of change in the site of accumulation in comparison with the previous measure is indicative that the therapy administered to the subject is efficacious, or
wherein a significant increase in the site of accumulation in comparison with the previous measure is indicative that the therapy administered to the subject is inefficacious.

### Claim 42 (depends on 25)

A method for treating a subject suffering from lung cancer, comprising administering a treatment selected from surgical removal of the lung tumor and/or administration of chemotherapy and/or radiotherapy, wherein the subject is identified by the diagnosis method of claim 25.

### Claim 43 (depends on 40)

A method for treating a subject suffering from lung cancer, comprising administering a treatment selected from surgical removal of the lung tumor and/or administration of chemotherapy and/or radiotherapy, wherein the progression of lung cancer in the subject is assessed by the monitoring method of claim 40.
